{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:12:20Z","timestamp":1788415940970,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Among non-small cell lung cancer (NSCLC) cases, anaplastic lymphoma kinase (ALK)-positive disease is characterized by a chromosomal rearrangement that generates an oncogenic ALK fusion gene, occurring in approximately 2\u201311% of patients. ALK-positive NSCLC is associated with a high incidence of brain metastases, with at least 20% of patients presenting with brain metastases at the time of diagnosis. Conversely, intraspinal metastasis is an uncommon site of metastatic involvement in patients with NSCLC. When intraspinal metastases invade the lumbar spinal canal, they may cause low back pain as well as neurological symptoms and signs in the lower limbs. Herein, we report a case of intraspinal metastasis in a patient with ALK\u2013EML4 fusion\u2013positive lung adenocarcinoma. Notably, at the time of initial relapse, molecular profiling failed to detect any mutations in the epidermal growth factor receptor (EGFR) or ALK genes. However, next-generation sequencing performed at the third recurrence confirmed the presence of the ALK\u2013EML4 fusion mutation. Following the fifth disease recurrence, the patient received palliative radiotherapy followed by combination targeted therapy with lorlatinib and anlotinib, and subsequently transitioned to maintenance therapy with lorlatinib, achieving an overall survival of 121 months (right-censored, t+) and a duration of treatment of 48 months (t+) with lorlatinib as fifth-line therapy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1916641","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:00Z","timestamp":1788412440000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advanced ALK\u2013EML4 fusion\u2013positive non-small cell lung cancer with intraspinal metastases: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Juan","family":"Lang","sequence":"first","affiliation":[{"name":"Department of Pathology, Shaoxing People\u2019s Hospital","place":["Shaoxing, Zhejiang, China"]},{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoyu","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Han","sequence":"additional","affiliation":[{"name":"Department of General Practice, Tashan Community Health Service Center of Yuecheng District","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkui","family":"Xiong","sequence":"additional","affiliation":[{"name":"School of Medicine, Shaoxing University","place":["Shaoxing, Zhejiang, China"]},{"name":"Department of Radiation Oncology, Shaoxing Second Hospital","place":["Shaoxing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA: A Cancer J For Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Center"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1571980","article-title":"The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer","volume":"13","author":"Yan","year":"2025","journal-title":"Front Public Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.annonc.2026.05.692","article-title":"Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study","volume":"37","author":"Shaw","year":"2026","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201425","article-title":"Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies","volume":"13","author":"Petrelli","year":"2018","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.20960","article-title":"A case of five-year survival after combined-modality treatment for non-small cell lung cancer with intraspinal metastasis","volume":"14","author":"Nieder","year":"2022","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000039196","article-title":"Primary intraspinal neuroendocrine tumor: A case report and literature review","volume":"103","author":"Dai","year":"2024","journal-title":"Medicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4103\/ijc.ijc_74_19","article-title":"Management of leptomeningeal metastases in non-small cell lung cancer","volume":"56","author":"Patil","year":"2019","journal-title":"Indian J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3779\/j.issn.1009-3419.2025.101.06","article-title":"Analysis of risk factors for meningeal metastasis in patients with lung adenocarcinoma following non-surgical interventions","volume":"28","author":"Yue","year":"2025","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3061","article-title":"The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18132169","article-title":"Leptomeningeal metastasis in non-small-cell lung cancer with actionable genomic alterations: Pathogenesis, diagnosis, and emerging therapeutic strategies","volume":"18","author":"Lim","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12967-022-03451-2","article-title":"Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC","volume":"20","author":"Wang","year":"2022","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2026.109416","article-title":"Immune-related gene expression profiling and alectinib efficacy for patients with ALK-rearranged non-small cell lung cancer: exploratory analysis of a prospective observational study","volume":"216","author":"Kurosaki","year":"2026","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s291801","article-title":"A phase I trial of the MET\/ALK\/ROS1 inhibitor crizotinib combined with the VEGF inhibitor pazopanib in patients with advanced solid Malignancies","volume":"14","author":"Piha-Paul","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14801","article-title":"VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers","volume":"112","author":"Watanabe","year":"2021","journal-title":"Cancer Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of non-small-cell lung cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13143","article-title":"Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients","volume":"10","author":"Haratake","year":"2019","journal-title":"Thorac Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15777","article-title":"Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer","volume":"114","author":"Goto","year":"2023","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-644","article-title":"International consensus on radiotherapy in metastatic non-small cell lung cancer","volume":"11","author":"Zhu","year":"2022","journal-title":"Trans Lung Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1145","article-title":"A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player","volume":"9","author":"Zhou","year":"2020","journal-title":"Trans Lung Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00781","article-title":"Tumor primary site and histology subtypes role in radiotherapeutic management of brain metastases","volume":"10","author":"Khan","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:14:02Z","timestamp":1788412442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1916641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1916641"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1916641","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1916641"}}